EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth

Asimina Zisi iD, Dimitris C Kanellis iD, Simon Moussaud iD, Ida Karlsson, Helena Carén iD, Lars Bräutigam, Jiri Bartek iD, Mikael S Lindström iD

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noac286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Asimina Zisi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Zebrafish, Glioma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: King Gustaf V´s Jubilee Foundation, Swedish Cancer Society, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-grade gliomas are malignant brain tumors characterized by aggressiveness and resistance to chemotherapy. Prognosis remains dismal, highlighting the need to identify novel molecular dependencies and targets. Ribosome biogenesis (RiBi), taking place in the nucleolus, represents a promising target as several cancer types rely on high RiBi rates to sustain proliferation. Publicly available transcriptomics data of glioma patients revealed a positive correlation between RiBi rates and histological grades. We, therefore, hypothesized that glioma cells could be susceptible to RiBi inhibition.

Methods

Transcriptomics data from glioma patients were analyzed for RiBi-related processes. BMH-21, a small molecule inhibitor of RNA pol I transcription, was tested in adult and pediatric high-grade glioma cell lines and a zebrafish transplant model. Cellular phenotypes were evaluated by transcriptomics, cell cycle analysis, and viability assays. A chemical synergy screen was performed to identify drugs potentiating BMH-21-mediated effects.

Results

BMH-21 reduced glioma cell viability, induced apoptosis, and impaired the growth of transplanted glioma cells in zebrafish. Combining BMH-21 with TMZ potentiated cytotoxic effects. Moreover, BMH-21 synergized with Fibroblast Growth Factor Receptor (FGFR) inhibitor (FGFRi) Erdafitinib, a top hit in the chemical synergy screen. RiBi inhibition using BMH-21, POLR1A siRNA, or Actinomycin D revealed engagement of the FGFR–FGF2 pathway. BMH-21 downregulated FGFR1 and SOX2 levels, whereas FGF2 was induced and released from the nucleolus.

Conclusions

This study conceptualizes the implementation of RiBi inhibition as a viable future therapeutic strategy for glioma and reveals an FGFR connection to the cellular response upon RiBi inhibition with potential translational value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZebrafishGliomaAnimalsFibroblast Growth Factor 2Cell Line, TumorCell ProliferationCell CycleProtein Kinase InhibitorsRibosomes

Stichwörter der Autor:innen

FGFR1/FGF2 signalingRNA polymerase Icombination therapyglioblastomaribosome biogenesis

Substanzen

Fibroblast Growth Factor 2Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Science for Life Laboratory, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Science for Life Laboratory, CBCS, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Comparative Medicine, Karolinska Institute, Stockholm, Sweden.
  • Danish Cancer Society Research Center, Copenhagen, Denmark.

ORCID-Profile: Asimina Zisi, Dimitris C Kanellis, Simon Moussaud, Helena Carén, Jiri Bartek, Mikael S Lindström

Förderung

  • King Gustaf V´s Jubilee Foundation
  • Swedish Cancer Society
  • Swedish Research Council

Zitieren

APA

Zisi, A., Kanellis, D. C., Moussaud, S., Karlsson, I., Carén, H., Bräutigam, L., Bartek, J., & Lindström, M. S. (2023). Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac286

Vancouver

Zisi A, Kanellis DC, Moussaud S, Karlsson I, Carén H, Bräutigam L, et al. Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth. Neuro-Oncology. 2023. doi:10.1093/neuonc/noac286

BibTeX
@article{Zisi2023,
  author = {Zisi, Asimina and Kanellis, Dimitris C and Moussaud, Simon and Karlsson, Ida and Carén, Helena and Bräutigam, Lars and Bartek, Jiri and Lindström, Mikael S},
  title = {Small molecule-mediated disruption of ribosome biogenesis synergizes with FGFR inhibitors to suppress glioma cell growth},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noac286}
}
Kostenlos starten →